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A B S T R A C T
Purpose: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to
assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality.
Methods: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008
and 2015.Patients were stratified into three age groups:< 65 years,65 to 80 years,and≥80 years.The area
under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of
the CCI to predict mortality risk.
Results: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502≥80 years) were
enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age
groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups
(14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the<65-year group
(20.3%,< 65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality
(3.2%,< 65 years; 5.5%, 65-80 years;7.6%,≥80 years; p=0.003).Independent predictors of mortality were
age≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI≥ 3 (HR:1.62; 95%
CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were
compared,the AUROC curve for CCI was significantly larger for patients aged< 65 years(p < 0.001) for both
in-hospital and 1-year mortality.
Conclusion: There were no differences in the clinical presentation of IE between the groups. Age≥80 years, high
comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in
patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk
of in-hospital and 1-year mortality after surgery, especially in the<65-year group.
1. Introduction
Infective endocarditis (IE) is a life-threatening disease with high
morbidity and mortality [1–4]. Its incidence in older patients has in-
creased for different reasons, such as the aging of the general popula-
tion and the increasing percentage of comorbidities [5–14]. Clinical
presentation seems to be similar between the younger and older po-
pulation [15–19]; however, there is no agreement on the role of age in
general mortality or in the mortality related to surgery as a treatment
for IE [2,8,10].
On the other hand, international guidelines have established the
indication for surgery (repair or valve replacement) in certain
situations, such as valve dysfunction resulting in heart failure, abscess,
recurrent embolic events with residual vegetation, persistent bacter-
aemia, or especially aggressive microorganisms (i.e., Staphylococcus
aureus) [20–22]; however, there are no recommendations in the
guidelines addressing the elderly population. Moreover, in patients
with IE, several scores have been proposed to predict early mortality
after surgery with the goal of helping physicians make the most ap-
propriate surgical decision. Although these scores could be applied to
elderly patients, a specific risk score system for this population may be
necessary [13,23,24].
Among scores of burdens of chronic diseases, the Charlson
Comorbidity Index (CCI) [25,26] is a well-known scale designed to
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estimate the baseline situation and prognosis of patients based on a
range of medical conditions. Easy to apply, objective, and reproducible,
the classical “3-points-cutoff” of the CCI has been studied in different
clinical situations [27–29], and it has been related to a high burden of
comorbidity.
The objectives of our study were to analyse the epidemiological
characteristics of IE in three different age groups of patients
(<65 years, 65–79 years, and≥80 years) and to assess the weight of
aging and comorbidity to predict the in-hospital and 1-year mortality
risk in each group.
2. Methods
2.1. Study population
All consecutive patients with definite or possible IE, according to
the modified Duke criteria [30,31], were prospectively included in the
Spanish Collaboration on Endocarditis—Grupo de Apoyo al Manejo de
la Endocarditis infecciosa en España (GAMES) registry maintained by
39 Spanish hospitals from January 2008 to April 2015. Multi-
disciplinary teams, including infectious disease physicians, cardiolo-
gists, heart surgeons, echocardiographers, microbiologists, and imaging
specialists, completed standardized case report forms with IE episode
and follow-up data that included clinical, microbiological, and echo-
cardiographic sections [32].
2.2. Ethics
The study was performed in accordance with the Declaration of
Helsinki. The protocol was reviewed and approved by the Institutional
Ethics Committee at all participating hospitals, according to local
standards. Informed consent was obtained from each patient.
2.3. Definitions and data collection
Active IE was defined as endocarditis with at least one of the
Table 1
Characteristics of 3120 patients diagnosed with IE according to three age groups.
Patients < 65y N=1327 Patients 65-79y
N=1291
Patients≥ 80y
N=502
p-valuea
Male gender, n (%) 987 (74.4) 835 (64.7) 286 (57.2) <0.001
Comorbidities, n (%)
Chronic pulmonary disease 174 (15) 280 (24.3) 107 (23.7) <0.001
Coronary arterial disease 251 (19) 388 (30.1) 129 (25.7) <0.001
Congestive heart failure 336 (25.4) 468 (36.3) 203 (40.5) <0.001
Diabetes mellitus 272 (20.5) 433 (33.6) 154 (30.7) <0.001
Solid organ transplant recipients 35 (2.6) 20 (1.6) 0 (0) 0.001
Moderate/severe renal disease 170 (12.8) 213 (16.5) 107 (21.4) <0.001
Moderate/severe liver disease 83 (6.3) 44 (3.4) 5 (1) <0.001
Charlson Comorbidity Index ≥3 405 (30.6) 522 (40.6) 232 (46.2) <0.001
Baseline Cardiac Status, n(%)
Congenital cardiac disease 158 (11.9) 18 (1.4) 4 (0.8) <0.001
Degenerative valvular disease 487 (36.7) 597 (46.2) 275 (54.8) <0.001
Previous IE 135 (10.2) 77 (6) 21 (4.2) <0.001
Previous cardiac surgery 382 (28.9) 530 (41.1) 158 (31.6) <0.001
Clinical features at presentation, n (%)
Fever 1100 (82.9) 1057 (81.9) 409 (81.4) 0.274
Arterial emboli 429 (32.3) 346 (26.8) 121 (24.1) 0.001
New valvular regurgitation 498 (37.5) 426 (33.0) 159 (31.7) 0.050
Splenomegaly 229 (17.3) 124 (9.6) 27 (5.4) <0.001
Heart failure 521 (39.2) 521 (40.4) 205 (40.8) 0.893
Heart block 103 (7.8) 118 (9.1) 44 (8.8) 0.325
Acute renal insufficiency 391 (29.5) 551 (42.7) 189 (37.6) <0.001
Angor 9 (0.7) 16 (1.4) 14 (3) 0.003
Septic shock 187 (14.1) 134 (10.4) 43 (8.6) 0.003
Epidemiological characteristics of IE, n (%)
Natural valve affected 896 (67.5) 713 (55.2) 311 (62) <0.001
Prosthetic valve affected 324 (24.4) 482 (37.3) 132 (26.3) <0.001
Endovascular device 143 (10.8) 150 (11.3) 82 (16.3) 0.004
Site of acquisition
Community 837 (63.1) 666 (51.6) 284 (56.7) <0.001
Nosocomial 321 (24.4) 458 (35.5) 16.5 (30.7)
Health care related 124 (9.4) 104 (8.1) 41 (8.2)
Type of affected valve
Aortic 605 (45.6) 685 (53.1) 227 (45.2) <0.001
Mitral 575 (43.3) 555 (43) 220 (43.8) 0.948
Pulmonary 37 (2.8) 8 (0.6) 0 (0) <0.001
Tricuspid 108 (8.1) 43 (3.3) 17 (3.4) <0.001
Etiology, n (%)
S. aureus 318 (24.0) 276 (21.4) 100 (19.9) 0.099
CNS 202 (15.2) 273 (21.1) 72 (14.3) <0.001
S. bovis 66 (6.0) 89 (6.9) 43 (8.6) 0.013
S. viridans 165 (12.4) 104 (8.1) 49 (9.7) 0.001
Enterococcus spp. 130 (9.8) 205 (15.8) 96 (19.1) <0.001
Gramnegative bacilli 65 (4.9) 42 (3.3) 18 (3.6) 0.88
Candida spp. 20 (1.5) 26 (2.0) 8 (1.6) 0.590
Polimicrobial IE 28 (2.1) 25 (1.9) 8 (1.6) 0.856
No etiology 122 (9.2) 113 (8.8) 48 (9.6) 0.848
IE: infective endocarditis; CoNS: coagulase-negative staphylococci.
a Two-tailed Chi-squared test or Fisher's exact test as appropriate in each case.
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following: positive blood cultures, fever, leucocytosis, raised in-
flammation markers, or current antibiotic treatment [30,31]. Micro-
biological diagnosis was made by blood, valve cultures, and/or mole-
cular techniques. Transthoracic and transoesophageal
echocardiography were performed on patients with clinical or micro-
biological suspicion of IE. To assess comorbidity, the CCI was calculated
[23,24]. In-hospital mortality was defined as death, regardless of its
cause, that occurred during the hospital admission. One-year mortality
was defined as death, regardless of its cause, that occurred within 1 year
after hospital discharge. Indication of surgical treatment was con-
sidered based on the criteria of American Heart Asociation21 and Eur-
opean Society of Cardiology [22].
Data from patients with IE were analysed, including epidemiolo-
gical and medical conditions, heart valve involvement, clinical mani-
festations at IE presentation, microorganisms identified, the appro-
priateness of antibiotic treatment used (defined as appropriate when
the selected antibiotic was sensitive to an isolated microorganism, and
the dose, dosing interval and duration of treatment were adequate ac-
cording to the guidelines of IE), and morbidity and mortality during
hospitalization. We also evaluated indications for surgery treatment,
whether there was a consultation with the cardiac surgery team and its
recommendation, and what were the reasons for not performing the
surgery. All patients were followed for at least 1-year post-discharge.
2.4. Statistical analyses
Quantitative variables were expressed as mean and standard deviation
(SD); qualitative variables were expressed as frequency and percentage.
Statistical analysis was performed using a two-tailed χ2 test and a Fisher's
exact test, or an analysis of variance test, as appropriate in each case. In-
hospital mortality and 1-year mortality were defined as all-cause mor-
tality. A multivariate Cox regression model was adjusted to estimate sur-
vival rate over time as a function of several covariates. Hazard ratios (HRs)
and their 95% confidence intervals (CIs) were calculated. The area under
the receiver-operating characteristic (AUROC) curve with a 95% CI was
calculated to quantify the diagnostic accuracy of the CCI to predict mor-
tality risk. Sensitivity, specificity, and positive and negative predictive
values and their 95% CIs were calculated.
A two-tailed p<0.05 was considered statistically significant. Data
were analysed using SPSS package v19.0 (SPSS Inc., Chicago, IL) and
Stata statistical software (Release 11.0, Stata Corporation, College
Station, TX).
3. Results
3.1. Patients characteristics
During the study period, 3120 patients (67.5% men) with definite or
possible IE were enrolled: 1327 (42.6%) patients <65 years, 1291
(41.4%) between 65 and 79 years, and 502 (16%) ≥80 years. Overall,
the mean follow-up of IE patients was 386.0 days (range, 14–698 days).
The patients' comorbidities conditions, baseline cardiac status, and
clinical and epidemiological characteristics of IE among all three groups
are shown in Table 1. The group aged ≥80 years had a significantly
higher percentage of cases with CCI≥ 3 (46.2%), degenerative valvular
disease (54.8%), renal disease (21.4%), affected natural valve (62%),
and endovascular device IE (16.3%) than patients in other age groups.
There were no differences among age groups in the proportion with
Table 2
Treatment and outcome of 3120 patients with endocarditis in the three age groups.
Patients < 65y N=1327 Patients 65-79y N=1291 Patients≥ 80y N=502 p-valuea
Treatment, n(%)
Appropriate antimicrobial treatment 1268 (95.5) 1233 (95.5) 476 (94.8) 0.828
Surgical indication 898 (67.7) 858 (66.5) 261 (52.0) <0.001
Surgical performance 709 (53.4) 594 (46.0) 104 (20.7) <0.001
Indications for surgery, n(%)
Severe regurgitation 346 (26.1) 230 (17.8) 49 (9.8) <0.001
Myocardial affectation 127 (9.6) 122 (9.5) 23 (4.6) 0.002
Persistence of sepsis 62 (4.7) 60 (4.6) 20 (4.0) 0.815
Aggressive microorganism 169 (12.7) 152 (11.8) 28 (5.6) <0.001
Recidive of IE 15 (1.1) 11 (0.9) 1 (0.2) 0.166
Prosthetic IE
Early 59 (4.4) 93 (7.2) 8 (1.6) <0.001
Late 85 (6.4) 79 (6.1) 19 (3.8) 0.099
Heart failure 319 (24.0) 278 (21.5) 66 (13.1) <0.001
Systemic emboli 72 (5.4) 43 (3.3) 13 (2.6) 0.006
Reasons for NO surgery, n(%)
Ictus 33 (2.5) 47 (3.6) 18 (3.6) 0.231
Intracranial hemorrhage 29 (2.2) 16 (1.2) 6 (1.2) 0.094
Hemodynamic instability 43 (3.2) 67 (5.2) 24 (4.8) 0.050
Complexity of surgery 24 (1.8) 38 (2.9) 26 (5.2) 0.001
Negative of patient 21 (1.6) 43 (3.3) 50 (10.0) <0.001
Negative of surgeon 58 (4.4) 81 (6.3) 48 (9.6) <0.001
Death 24 (1.8) 28 (2.2) 17 (3.4) 0.154
Complications after surgery, n(%)
Ictus 6 (0.5) 14 (1.1) 3 (0.6) 0.150
Intracranial hemorrhage 13 (1.0) 10 (0.8) 1 (0.2) 0.258
Hemodynamic instability 102 (7.7) 117 (9.1) 18 (3.6) 0.001
Surgical site infection 6 (0.5) 5 (0.4) 5 (1.0) 0.218
Nosocomial pneumonia 37 (2.8) 44 (3.4) 10 (2.0) 0.273
Sepsis related to catheter 12 (0.9) 20 (1.5) 1 (0.2) 0.034
Renal failure 74 (5.6) 95 (7.4) 15 (3.0) 0.002
Cardiac blockage 35 (2.6) 35 (2.7) 9 (1.8) 0.562
Outcome, n(%)
In-hospital mortality 270 (20.3) 388 (30.1) 174 (34.7) <0.001
1-year mortality 60 (11.2) 95 (11.7) 59 (20.4) <0.001
IE: infective endocarditis. MOD: multiple organ dysfunction. CNS: coagulase-negative Staphylococci.
a Two-tailed Chi-squared test or Fisher's exact test (as appropriate in each case).
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fever as a clinical presentation of IE. However, patients aged <65 years
presented a significantly higher frequency of septic shock (14.1%), new
valvular regurgitation (37.5%), and splenomegaly (17.5%). Other
clinical data presented at the time of the diagnosis are shown in Table 1.
3.2. Etiology
Overall, S. aureus was the most common microorganism isolated
(22.2%), followed by coagulase-negative staphylococci (CoNS)
(17.5%), Enterococcus spp. (13.8%), and Streptococcus viridans (10.2%).
S. viridans was significantly more common in patients aged <65 years
(12.4%), while CoNS was prevalent in the 65- to 80-year group (21.1%)
and both Streptococcus bovis and enterococci were noted in the ≥80-
year group (8.6% and 19.1%, respectively). Gram-negative bacilli and
Candida spp. were similar among groups, as was the proportion of IE
without microbiologic isolation (Table 1).
3.3. Treatment
The appropriateness of antibiotic treatment in the three groups of
patients was >90%, without statistically significant differences be-
tween them (Table 2). There was a significant difference between the
proportion of patients who had surgical indication and those who un-
derwent surgery; this difference increased significantly with age:
14.3%, 20.5%, and 31.3% in patients <65 years, 65 to 79 years,
and≥80 years, respectively. Patients ≥80 years who underwent sur-
gery had significantly less hemodynamic instability (3.6%), renal
failure (3%), and cardiac blockage (1.8%) as complications of surgery
than the other groups of patients (Table 2).
3.4. Outcome
In the ≥80-year group, there was a significantly higher in-hospital
mortality (34.7%) and one-year mortality (20.4%) (Table 2). To analyse
the role of age, comorbidity, and performance of surgery on mortality,
multivariate Cox regression models were performed (Table 3). The main
independent predictors of mortality were septic shock (adjusted HR: 2.78
[95% CI: 2.32–3.34] and age≥80 years (adjusted HR: 2.05 [95% CI:
1.67–2.50]). CCI≥3presented an adjusted HR of 1.62 (95% CI:
1.39–1.88), and non-performance of surgery had an adjusted HR of 1.36
(95% CI: 1.16–1.58).
Patients with surgical indication (n=2011) were analysed separately,
comparing their outcome regarding whether or not surgery was per-
formed. There were many significant differences in the characteristics
between the 2 groups, with higher values among non-operated patients,
highlighting the following variables: proportion of patients aged
≥80 years (25% vs. 7.2%), CCI≥3 (48.4% vs. 29.6%), sepsis with mul-
tiple organ dysfunction (24.2% vs. 15.5%), S. aureus IE (30.4% vs. 17.6%),
in-hospital mortality (54.4% vs. 22.2%), and 1-year mortality (21.3% vs.
6.6%). Other significant differences are shown in Table 4.
Among patients who finally underwent surgery (n=1370), those
with CCI≥ 3 had significant differences in the distribution of the fol-
lowing variables: male gender, age, septic shock, in-hospital mortality,
and 1-year mortality (Table 5).
Table 3
Predictors of mortality in 3120 patients with IE.
HR (95% CI) Adjusted HRa (95% IC)
Age, years
< 66 1 1
66–80 1.59 (1.38–1.84) 1.56 (1.32–1.84)
>80 2.17 (1.83–2.58) 2.05 (1.67–2.50)
Age, years (per year) 1.023 (1.018–1.028) 1.021 (1.016–1.027)
Female sex (ref.: male) 1.34 (1.18–1.52) 1.14 (0.98–1.32)
Charlson Comorbidity Index ≥3 1.93 (1.69–2.20) 1.62 (1.39–1.88)
Prosthetic valve IE 1.23 (1.08–1.40) 1.16 (1.00–1.35)
Nosocomial IE 1.56 (1.37–1.78) 1.21 (1.04–1.40)
Sepsis with MOD 2.60 (2.26–2.99) 1.72 (1.46–2.04)
Septic shock 3.80 (3.28–4.39) 2.78 (2.32–3.34)
Abscess 1.65 (1.41–1.93) 1.60 (1.34–1.91)
S. aureus IE 1.70 (1.48–1.94) 1.34 (1.14–1.58)
No surgery 1.64 (1.44–1.87) 1.36 (1.16–1.58)
IE: infective endocarditis. HR: hazard ratio; CI: confidence interval. MOD:
multiple organ dysfunction.
a Multivariate Cox regression: adjusted by age, sex, Charlson Index≥3, no-
socomial valve IE, prosthetic valve IE, presence of abscess, sepsis with MOD,
septic shock, S. aureus IE and performance of surgery.
Table 4
Characteristics of 2011 patients with IE and surgical indication, according to
performance of surgery.
Surgery
(n=1368)
No surgery
(n=643)
p-valuea
Male, n(%) 1015 (74.3) 409 (63.5) <0.001
Age (years), mean value± SD 62.2 (15.5) 69.5 (14.7) <0.001
Age < 65y, n (%) 694 (50.7) 204 (31.4) <0.001
Age 65–79, n (%) 577 (42.11) 281 (43.43) 0.577
Age≥80y, n (%) 99 (7.2) 162 (25) <0.001
CCI, mean value± SD 1.9 (1.8) 2.9 (2.3) <0.001
CCI ≥3, n (%) 405 (29.6) 311 (48.4) <0.001
Type of IE, n (%)
Native 775 (56.6) 408 (63.1) 0.006
Prosthesis 976 (71.2) 419 (64.8) 0.003
Fever, n(%) 1087 (79.9) 552 (85.7) 0.002
New valvular regurgitation, n
(%)
802 (58.7) 400 (62.1) 0.147
Heart failure, n(%) 676 (49.4) 347 (53.8) 0.064
Sepsis with MOD, n(%) 212 (15.5) 156 (24.2) <0.001
Septic shock, n(%) 148 (10.8) 128 (19.8) <0.001
Main microorganisms, n(%)
S. aureus 241 (17.6) 197 (30.4) <0.001
CNS 311 (22.7) 110 (17) 0.003
S. bovis 62 (5.2) 34 (5.9) 0.525
S. viridans 152 (12.8) 47 (8.2) 0.005
In-hospital mortality, n (%) 304 (22.2) 352 (54.4) <0.001
One-year mortality, n (%) 64 (6.6) 57 (21.3) <0.001
IE: infective Endocarditis. SD: standard deviation. CCI: Charlson Comorbidity
Index. MOD: multiple organ dysfunction. CNS: coagulase-negative
Staphylococci.
a Two-tailed Chi-squared test or Fisher's exact test (as corresponding) for
categorical variables and ANOVA test for continuous variables.
Table 5
Characteristics of 1370 patients with IE operated, grouped by Charlson
Comorbidity Index (CCI) score<3 and ≥ 3.
CCI≥3
(n=406)
CCI < 3
(n=964)
p-valuea
Male, n(%) 317 (78.0) 698 (72.6) 0.042
Age (years), mean value±
SD
65.8 (12.3) 60.6 (16.4) <0.001
Age < 65y, n (%) 186 (45.81) 523 (54.2) 0.004
Age 65–79, n (%) 183 (45.07) 380 (39,5) 0.066
Age≥80y, n (%) 37 (9.1) 61 (6.3) 0.084
Prosthetic IE, n (%) 288 (71.7) 687 (71.3) 0.932
Fever, n(%) 324 (80.8) 762 (79.5) 0.598
Heart failure, n(%) 206 (50.9) 468 (48.6) 0.454
Sepsis with MOD, n(%) 73 (18.0) 139 (14.4) 0.094
Septic shock, n(%) 57 (14.1) 90 (9.3) 0.010
S. aureus IE, n(%) 79 (19.5) 162 (16.2) 0.234
In-hospital mortality, n(%) 125 (30.9) 178 (18.5) <0.001
One-year mortality, n(%) 28 (10.9) 36 (5.1) 0.001
IE: infective Endocarditis. CCI: Charlson Comorbidity Index. SD: standard de-
viation. MOD: multiple organ dysfunction.
a Two-tailed Chi-squared test or Fisher's exact test (as corresponding) for
categorical variables and ANOVA test for continuous variables.
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From these results, we analysed whether CCI≥ 3 could predict in-
hospital and 1-year mortality among patients with surgical indication,
helping to select the best candidates for surgery (Table 4). Overall, for
in-hospital mortality, CCI≥ 3 showed a sensitivity and specificity of
48.2% and 70.5%, respectively; the PPV was 44.0% and NPV 73.8%.
For 1-year mortality, CCI≥ 3 showed a sensitivity and specificity of
47.1% and 72.2%, respectively, with a PPV of 15.5% and NPV of 92.6%
(Table 6).
The AUROC for CCI was 0.64 (CI: 0.62–0.67) for the prediction of
in-hospital mortality (Fig. 1 A) and 0.65 (CI: 0.60–0.70) for 1-year
mortality (Fig. 1 C). When the three age groups compared, the AUROC
curve for CCI was significantly larger for patients aged <65 years than
for those aged 65 to 79 years or≥ 80 years for in-hospital mortality
(0.67 [95% CI: 0.63–0.71] vs. 0.62 [95% CI: 0.58–0.66] vs. 0.54 [95%
CI: 0.48–0.61], respectively; p<0.001; Fig. 1B). These results were
similar for 1-year mortality: age<65 years: 0.70 (95% CI: 0.61–0.79),
age 65 to 79 years: 0.63 (95% CI: 0.55–0.71), and≥80 years: 0.46
(95% CI: 0.34–0.58; p<0.001; Fig. 1D).
4. Discussion
This multicentric prospective study evaluates the main epidemio-
logical characteristics of patients with IE in different age groups. It is
worth noting the high proportion of older patients with IE in our study,
since this special population currently presents an increasing incidence
of IE [5,7,9,10]. As it has been observed in other studies, IE was more
frequent in male patients, probably due to the higher proportion of
valvular disease in this population. [14,19]. The increasing in the
proportion of female patients with age could be related to the higher
life expectancy of women [8]. It is accepted that older patients pre-
sented more comorbidities [8,14,15]. We found two exceptions: the
presence of liver disease and the percentage of solid organ transplant
recipients, both of them more frequent in younger patients. First con-
dition could be related to the higher mortality of patients with ad-
vanced liver disease. Solid organ transplants are also performed more
frequently in younger patients, although due to the small proportion of
patients is difficult to draw conclusions about this finding.
Fever and heart failure were the most common presentations of IE,
with no differences among age groups. These results are consistent with
the current evidence since, although it has been usually accepted that
clinical features are less marked in older people than in younger pa-
tients [2,10], recent studies do not find clear differences in clinical
presentation between both groups [14,15]. The higher frequency of a
new heart murmur in the <65-year group could be related to the
misattribution of cardiac murmurs in older patients to degenerative
valvular disease, which is more frequent in this population. Therefore,
the diagnosis of IE could be challenging, but main signs and symptoms
of presentation do not seem very different between younger and older
patients.
Cases of IE with S. viridans isolation were more common in patients
aged <65 years, while cases of IE with S. bovis and Enterococcus spp.
isolation were more prevalent in patients older than 80 years, probably
related to the more frequent odontogenic origin of IE in the younger
population and to the gastrointestinal and genitourinary origin in oc-
togenarian patients [8,14,15,33]. The isolation of the CoNS was more
frequent in the group of 65 to 79 years, which could be explained by the
higher proportion of prosthetic valve IE and nosocomial IE among these
patients [5,8]. Similarly, to other studies, we did not find differences
among all three groups in the proportion of gram-negative bacilli and
Candida spp. IE, as well as in the proportion of IE without microbiologic
isolation [14,19].
Mortality among our patients was high, especially in elder patients,
as has been remarked in other studies [2,7,15,17,33,34]. There is no
doubt that the greater degree of comorbidity that these patients pre-
sented has contributed to this. On the other hand, the value of surgery
in the outcome of IE is well known [35]. Our data showed that in-
creasing age, in particular the oldest old patients (≥80 years), CCI≥ 3,
and non-performance of surgery were independently associated with
mortality.
In all three groups, the proportion in whom surgery was performed
was less than the surgical indication. However, we found that the
percentage of patients ≥80 years who underwent surgery was sig-
nificantly lower compared with other age groups. Only 21% of the
octogenarian group underwent surgery, although surgical intervention
was indicated in 52%. This fact means that 31% of patients aged
≥80 years with surgical indications did not undergo surgery, compared
with 14% or 20% in the groups of <65 years and 65 to 79 years, re-
spectively. Thus, in our cohort, the non-performance of surgery in pa-
tients in whom it was indicated could also contribute to the higher
mortality rate observed in older patients. The results agree with the
findings by Oliver et al. [19], who showed that very old patients with IE
could benefit from surgery, since mortality in surgical candidates
reached 72.7% in the case of medical treatment alone compared with
6.3% for patients who received both medical and surgical treatment. In
addition, in our study, patients ≥80 years who underwent surgery did
not present more complications than the other groups of patients and
had significantly fewer hemodynamic complications or renal failure.
Nonetheless, these results must be interpreted with caution since the
operated patients had a stricter selection and significantly less hemo-
dynamic instability or complexity of surgery than in the other age
groups. However, a negative of patient and a negative of surgeon were
the main reasons for non-performance of surgery in the older patients.
As suggested by Chirillo [13], age per se should not be a contra-
indication to surgery.
Given these findings, we studied whether the degree of comorbidity
calculated by the ICC could be useful to select patients with lower
Table 6
Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for CCI ≥3 to predict in-hospital and 1-year mortality in 2011 patients with
surgical indication for IE.
Dead (TP/total) Alive (TN/total) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
(95% CI) (95% CI) (95% CI) (95% CI)
CCI≥ 3 for In-hospital mortality
All patients 315/654 956/1357 48.2 (44.3–52.0) 70.5 (68.0–72.9) 44.0 (40.4–47.6) 73.8 (71.4–76.2)
Surgical indication and surgery 125/303 785/1065 41.3 (35.7–46.8) 73.7 (71.1–76.4) 30.9 (26.4–35.4) 81.5 (79.1–84.0)
Surgical indication and no surgery 190/351 171/292 54.1 (48.9–59.3) 58.5 (52.9–64.2) 61.1 (55.7–66.5) 51.5 (46.1–56.9)
CCI≥ 3 for one-year mortality
All patients 57/121 803/1113 47.1 (38.2–56.0) 72.1 (69.5–74.8) 15.5 (11.8–19.2) 92.6 (90.9–94.4)
Surgical indication and surgery 28/64 675/905 43.8 (31.6–55.9) 74.6 (71.7–77.4) 10.9 (7.6–14.6) 94.9 (93.6–96.5)
Surgical indication and no surgery 29/57 128/208 50.9 (37.9–63.9) 61.5 (54.9–68.2) 26.6 (18.3–34.9) 82.1 (76.0–88.1)
CCI: Charlson Comorbidity Index; IE: infective Endocarditis; TN: true negative; TP: true positive; CI: confidence interval; PPV: positive predictive value; NPV:
negative predictive value.
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surgical risk. The CCI was applied to all patients with surgical indica-
tion. The score showed a high negative predictive value for in-hospital
and 1-year mortality, especially in the group of patients aged <65 years
who underwent surgery. The modest value of the AUROC curve in
patients aged 65 to 80 years and in those ≥80 years make us take these
results with caution in those populations.
This study presents some limitations. It is part of a multicentre
collection of data, and some recordings of clinical or diagnostic
characteristics might be influenced by interobserver variability.
Second, not all participating hospitals have a Cardiovascular Surgery
Service, although all of them have a referral hospital, with cardio-
vascular surgeons as part of their IE teams. Finally, our data form did
not include scales of basal situation and frailty, which, if associated
with comorbidity, could better estimate the daily condition of older
patients with IE. Nevertheless, this study shows one of the largest
multicentric published cohorts, with a clearly established protocol,
which allows us to analyse the effect of age and comorbidity on the
outcome of IE.
In view of our results, we can conclude that mortality, both in-
hospital and at 1 year, remains high in IE, being age, comorbidity and
non-performance of surgery independent predictors of mortality.
Therefore, it is necessary to individualize the most appropriate treat-
ment in older patients, in order to identify best candidates of surgery in
that population. Preoperative multidisciplinary evaluation (cardiolo-
gist, cardiac surgeons, specialists in geriatrics, in infectious diseases) in
each patient is essential to evaluate the benefit and the risk of the op-
eration, and professionals with experience in the assessment of elderly
patients could enrich the IE teams.
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